Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Martha Turner

General Practice Riverton, WY Medical Doctor

NPI 1902809130 CMS profile 645158

1240 College View, Riverton, WY 82501

Open in the dashboard

General payments

$269

14 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Martha Turner of Riverton, WY is reported in the CMS Open Payments database as having received $269 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $12 1
2019 General $257 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martha Turner
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Martha Turner were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Martha Turner General Practice median Middle half National median
2019 $257 $107 $37–$285 $163
2020 $12 $75 $25–$213 $114
2021 $0 $93 $30–$272 $132
2022 $0 $103 $36–$279 $149
2023 $0 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Janssen Pharmaceuticals, Inc $70 1 payment
  2. AstraZeneca Pharmaceuticals LP $46 3 payments
  3. Merck Sharp & Dohme Corporation $42 3 payments
  4. Allergan Inc. $35 2 payments
  5. Novo Nordisk Inc $32 2 payments
  6. Novartis Pharmaceuticals Corporation $16 1 payment
  7. Amgen Inc. $16 1 payment
  8. Lilly USA, LLC $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $269 14 payments
Products named General payments · program years 2019–2020
  1. XARELTO $70 1 payment
  2. STEGLATRO $42 3 payments
  3. BELSOMRA $42 3 payments
  4. JANUVIA $42 3 payments
  5. Ozempic $32 2 payments
  6. DULERA $28 2 payments
  7. SYMBICORT $24 2 payments
  8. FARXIGA $22 1 payment
  9. BYSTOLIC $18 1 payment
  10. ENTRESTO $16 1 payment
  11. Other $85 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,742

Median for General Practice: 1,105

Drug cost

$117,953

Median for General Practice: $48,734

Branded share of claims

15.6%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 83 $52,043
Repatha Sureclick Evolocumab Brand 16 $16,606
Myrbetriq Mirabegron Brand 28 $15,341
Xarelto Rivaroxaban Brand 22 $12,453
Arnuity Ellipta Fluticasone Furoate Brand 12 $3,806
Levothyroxine Sodium Generic 220 $2,169
Atorvastatin Calcium Generic 153 $1,449
Lisinopril Generic 145 $1,220
Pantoprazole Sodium Generic 78 $1,048
Potassium Chloride Generic 54 $837

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$4,406

Medicare's payments for the services billed

Medicare patients

97

Average age 79

Services billed

158

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 43%
Diabetes 22%
Osteoporosis 22%
Heart failure 19%
Ischemic heart disease 18%
Depression 18%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record